Vulvar Lichen Simplex Chronicus Refractory to Biologic Therapy: What to Do When Dupilumab or Nemolizumab Has Not Worked

Lichen simplex chronicus involving the genital region presents a distinct clinical challenge: in this anatomically sensitive site, topical agents are often poorly tolerated, making systemic therapy the standard escalation path. When systemic biologic treatment also fails to achieve adequate relief, a further management step is needed.

Clinical scenario

Vulvar LSC in an anatomically sensitive area where topical agents are poorly tolerated — and where prior systemic biologic therapy has not achieved the treatment goals.

Prior line — insufficient response

Systemic biologic therapy with dupilumab (a monoclonal antibody targeting interleukin-4 and interleukin-13) or, where applicable, nemolizumab (an IL-31 receptor antibody) did not achieve the goals of relief of vulvar pruritus and thinning of lichenified skin. This protocol addresses the step taken after that failure.

Next-line approach

For refractory vulvar LSC unresponsive to biologic therapy, the next step involves procedural, device-based therapy — a category of intervention distinct from pharmacological options and applied directly to the affected tissue.

Full regimen details, sequencing, and clinical criteria are in the structured protocol.

Treatment goal

Marked improvement of vulvar LSC with sustained relief of pruritus.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-025-00979-z

In anatomically sensitive areas such as the genital region, where topical agents may be poorly tolerated, systemic treatments may be required.
A recent controlled study in 80 women with vulvar LSC compared ultra-pulse fractional CO2 laser versus topical steroids over 3–6 months.
High-frequency focused ultrasound is a novel device therapy mentioned in recent literature for vulvar LSC.
The laser-treated group had superior outcomes, with 82.5% showing marked improvement at 1 month (versus 65% of the steroid group) and a sustained 87.5% overall response at 6 months (versus 52.5% in the steroid group).

View source ↗